What is Hemab Therapeutics Holdings, Inc.'s (COAG) StockRank?

MoatMap's StockRank for Hemab Therapeutics Holdings, Inc. (COAG) is 11/100, with a Strong Sell signal. This is a composite score combining Quality (38), Value (26), and Momentum (22) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Hemab Therapeutics Holdings, Inc. have an economic moat?

Hemab Therapeutics Holdings, Inc. (COAG) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Hemab Therapeutics Holdings, Inc. a buy, hold, or sell?

MoatMap's current signal for Hemab Therapeutics Holdings, Inc. (COAG) is Strong Sell, based on a StockRank of 11/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Hemab Therapeutics Holdings, Inc. in?

Hemab Therapeutics Holdings, Inc. (COAG) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

COAG

Strong SellSinker

Hemab Therapeutics Holdings, Inc. · Healthcare · United States · $2.1B · Avg Vol: $15M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

—

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company dedicated to developing first-in-class prophylactic therapeutics for serious bleeding disorders. The company's competitive advantage is its focus on targeting under-served, rare bleeding conditions using bispecific antibodies and engineered proteins. It operates as a highly specialized niche player in the hematology space.

FINANCIAL SUMMARY (USD)

Year	2024	2025	TTM	2026E	2027E	Fwd CAGR
Revenue	0	0	—	—	—	—
EPS	-1.77	-2.33	-1.78	-3.10	-2.54	—
Shares	44.2M	44.2M	46.7M	—	—	—
Debt	1.7M	1.2M	1.0M	—	—	—
Equity	-115.3M	-176.6M	—	—	—	—
Op CF	-45.6M	-61.5M	-77.3M	—	—	—
Inv CF	61.9M	-81.5M	—	—	—	—
Fin CF	-0.1M	156.3M	—	—	—	—

Loading 1Y...

PRICE (1Y)-16.0%

SMA 50SMA 200

$39.88

RSI (14)

29.5

SCORE BREAKDOWN

Quality

ROIC

-38.1%20.3

ROE

—N/A

GP/Assets

—N/A

Op. Margin

0.0%38.1

FCF/Assets

-31.6%12.5

Piotroski

559.7

Int. Cover

—N/A

D/E Ratio

0.00x92.0

Current Ratio

35.85x98.6

Value

P/E (TTM)

—N/A

EV/EBITDA

-18.6x25.0

P/FCF

—N/A

P/B

4.6x31.9

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

—N/A

RS 6M

—N/A

SMA 50/200

—N/A

EPS Rev 4W

-1.0%25.3

EPS Rev 12W

-9.1%13.4

EPS Improve

-43%10.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$2.1B

P/E (Forward)

-17.5x

Gross Margin

—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of COAG are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
COAG	Hemab Therapeutics Holdings, Inc.(you)	$2.1B	11	Strong Sell
KLRA	Kailera Therapeutics, Inc.	$2.1B	11	Strong Sell
BRVE	Braveheart Bio, Inc.	$1.9B	11	Strong Sell
STOK	Stoke Therapeutics, Inc.	$2.0B	13	Strong Sell
KARD	Kardigan, Inc.	$1.9B	11	Strong Sell
ZBIO	Zenas BioPharma, Inc.	$2.0B	14	Strong Sell
KOD	Kodiak Sciences Inc.	$2.4B	12	Strong Sell
RXRX	Recursion Pharmaceuticals, Inc.	$1.8B	11	Strong Sell
INBX	Inhibrx Biosciences, Inc.	$1.8B	13	Strong Sell
TSHA	Taysha Gene Therapies, Inc.	$1.9B	13	Strong Sell

Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%

Hemab Therapeutics Holdings, Inc. (COAG): Stock Score Summary

Hemab Therapeutics Holdings, Inc. (COAG) has a MoatMap StockRank of 11/100 based on Quality (38/100), Value (26/100), and Momentum (22/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$39.88
Market Cap	$2.1B
P/E (Forward)	-17.50
Price/Book	4.57
Return on Invested Capital	-38.1%
Debt/Equity	0.00x
Operating Margin	0.0%
Free Cash Flow	$-61M

Hemab Therapeutics Holdings, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Hemab Therapeutics Holdings, Inc.’s (COAG) StockRank?: MoatMap’s StockRank for Hemab Therapeutics Holdings, Inc. (COAG) is 11/100, with a Strong Sell signal. It is a composite of Quality (38), Value (26), and Momentum (22) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Hemab Therapeutics Holdings, Inc. have an economic moat?: Hemab Therapeutics Holdings, Inc. (COAG) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Hemab Therapeutics Holdings, Inc. a buy, hold, or sell?: MoatMap’s current signal for Hemab Therapeutics Holdings, Inc. (COAG) is Strong Sell, based on a StockRank of 11/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Hemab Therapeutics Holdings, Inc. in?: Hemab Therapeutics Holdings, Inc. (COAG) operates in the Healthcare sector, specifically the Biotechnology industry (United States).